MXene-based CRISPR/Cas9 nanoplatform targeting FABP5 for ROS amplification and synergistic photothermal/photodynamic therapy of cervical cancer.

J Nanobiotechnology · 2026 · PMC13273998 · PMID 42036673

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Compared with the control group, the number of cells that migrated through the membrane in the MPF + L group decreased to less than 30%, showing a highly significant difference and a much stronger suppression than that observed in any single-treatment group.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.